LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Home・Akciju saraksts・Essa Pharma Inc

Essa Pharma Inc

Slēgts

0.2

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.19

Max

0.2

Galvenie mērījumi
By Trading Economics
Ienākumi	2.4M -4M
EPS	-0.14
Dividenžu ienesīgums	87.56
Peļņas marža	-4,681.422
Darbinieki	35
EBITDA	1.4M -5M

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	87.56% 3.12%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-73M 11M
Iepriekšējā atvēršanas cena	0.2
Iepriekšējā slēgšanas cena	0.2

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

1.7 / 1.72 Atbalsts un pretestība

Essa Pharma Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. sept. 22:41 UTC

Galvenie tirgus virzītāji

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

2025. g. 12. sept. 16:04 UTC

Galvenie tirgus virzītāji

Upexi Shares Climb on Solana Gains

2025. g. 14. sept. 23:48 UTC

Tirgus saruna

Oil Futures Mixed Amid Divergent Signals -- Market Talk

2025. g. 14. sept. 23:41 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2025. g. 14. sept. 23:38 UTC

Tirgus saruna

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 14. sept. 23:04 UTC

Tirgus saruna

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

2025. g. 13. sept. 08:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 20:09 UTC

Peļņas

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

2025. g. 12. sept. 19:23 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:16 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:03 UTC

Tirgus saruna

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

2025. g. 12. sept. 18:59 UTC

Tirgus saruna

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

2025. g. 12. sept. 18:38 UTC

Tirgus saruna

Peļņas

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

2025. g. 12. sept. 18:33 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

2025. g. 12. sept. 18:22 UTC

Tirgus saruna

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

2025. g. 12. sept. 16:56 UTC

Tirgus saruna

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

2025. g. 12. sept. 16:22 UTC

Peļņas

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

2025. g. 12. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025. g. 12. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 12. sept. 16:11 UTC

Peļņas

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

2025. g. 12. sept. 15:37 UTC

Tirgus saruna

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

2025. g. 12. sept. 15:22 UTC

Tirgus saruna

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

2025. g. 12. sept. 15:07 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Essa Pharma Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Essa Pharma Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.7 / 1.72Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.